Astrazeneca’s covid-19 vaccine articles
-
AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines
Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or suppliedAstraZeneca has begun the worldwide withdrawal of its Covid-19 vaccine due to a “surplus of available updated vaccines” that target new variants of the virus.The announcement follows the pharmaceutical company in March voluntarily withdrawing its European Union marketing authorisation, which is the approval to market a medicine in member states. Continue...
-
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients...
-
AstraZeneca pulls its COVID-19 vaccine from the European market
LONDON (AP) — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European Medicines Agency's website Wednesday, the regulator said that the approval for AstraZeneca's Vaxzevria had been withdrawn “at the request of the marketing authorization holder.” []